{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:19:55Z","timestamp":1778869195540,"version":"3.51.4"},"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Strategic Research Fund (SRF), Ministry of Science, Technology, and Innovation (MOSTI), Malaysia","award":["305.PPSK.614503"],"award-info":[{"award-number":["305.PPSK.614503"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>For more than a century, developing novel and effective vaccines against malaria and Tuberculosis (TB) infections has been a challenge. This review sought to investigate the reasons for the slow progress of malaria and TB vaccine candidates in sub-Saharan African clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The systematic review protocol was registered on PROSPERO on July 26, 2023 (CRD42023445166). The research articles related to the immunogenicity, efficacy, or safety of malaria or TB vaccines that were published between January 1, 2012, and August 31, 2023, were searched on three databases: Web of Science (WoS), PubMed, and ClinicalTrials.gov.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2342 articles were obtained, 50 of which met the inclusion criteria. 28 (56%) articles reported on malaria vaccine attributes, while 22 (44%) articles reported on TB vaccines. In both cases, the major challenges in sub-Saharan African clinical trials were immunogenicity and efficacy, rather than safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Factors such as population characteristics, pathogen genetic diversity, vaccine nature, strategy, and formulation were associated with slow progress of the malaria and TB vaccine candidates in sub-Saharan African clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0317233","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:37:23Z","timestamp":1737725843000},"page":"e0317233","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["A systematic review on malaria and Tuberculosis (TB) vaccine challenges in sub-Saharan African clinical trials"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3810-9074","authenticated-orcid":true,"given":"Maonezi Abas","family":"Hamisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4386-299X","authenticated-orcid":true,"given":"Nur Ain Mohd","family":"Asri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aini Syahida Mat","family":"Yassim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapeah","family":"Suppian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"pone.0317233.ref001","unstructured":"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. The top 10 causes of death."},{"key":"pone.0317233.ref002","article-title":"Malaria and tuberculosis as diseases of neglected populations: state of the art in chemotherapy and advances in the search for new drugs","author":"R Vinicius de Ara\u00fajo","year":"2020","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"pone.0317233.ref003","first-page":"1608","volume-title":"The Lancet","author":"EA Ashley","year":"2018"},{"key":"pone.0317233.ref004","unstructured":"WHO. World malaria report 2022 [Internet]. 2022. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme"},{"issue":"2","key":"pone.0317233.ref005","first-page":"93","article-title":"Climate, environment and transmission of malaria","volume":"24","author":"A Rossati","year":"2016","journal-title":"Infezioni in Medicina"},{"key":"pone.0317233.ref006","unstructured":"CDC. CDC\u2014Malaria\u2014Malaria Worldwide\u2014Impact of Malaria. 2021."},{"key":"pone.0317233.ref007","unstructured":"WHO. Global Tuberculosis report 2022 [Internet]. 2022. Available from: http:\/\/apps.who.int\/bookorders."},{"key":"pone.0317233.ref008","unstructured":"WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy. 2018."},{"key":"pone.0317233.ref009","unstructured":"WHO. World malaria report 2016. 2016. 148 p."},{"issue":"9","key":"pone.0317233.ref010","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/infdis\/jiac322","article-title":"Malaria Transmission Intensity Likely Modifies RTS, S\/AS01 Efficacy Due to a Rebound Effect in Ghana, Malawi, and Gabon","volume":"226","author":"GJ Bell","year":"2022","journal-title":"Journal of Infectious Diseases"},{"issue":"9","key":"pone.0317233.ref011","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","article-title":"Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial","volume":"7","author":"M Tameris","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"11","key":"pone.0317233.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078679","article-title":"A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in burkinabe healthy adults 18 to 45 years of age","volume":"8","author":"A Ou\u00e9draogo","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"pone.0317233.ref013","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/mt.2014.109","article-title":"Translating the Immunogenicity of Prime-boost Immunization with ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations","volume":"22","author":"D Kimani","year":"2014","journal-title":"MOLECULAR THERAPY"},{"issue":"45","key":"pone.0317233.ref014","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1016\/j.vaccine.2017.09.027","article-title":"Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel\u00ae in European and African adults: A phase 1a\/1b, randomized, double-blind multi-centre trial","volume":"35","author":"SB Sirima","year":"2017","journal-title":"Vaccine"},{"issue":"31","key":"pone.0317233.ref015","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1016\/j.vaccine.2021.06.024","article-title":"Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine","volume":"39","author":"S Dassah","year":"2021","journal-title":"Vaccine"},{"issue":"8","key":"pone.0317233.ref016","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/cid\/ciy1087","article-title":"Controlled Human Malaria Infection of Healthy Adults with Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2","volume":"69","author":"JC Dejon-Agobe","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"24","key":"pone.0317233.ref017","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A Phase 3 Trial of RTS, S\/AS01 Malaria Vaccine in African Infants","volume":"367","author":"Partnership","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"pone.0317233.ref018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01008","article-title":"RTS, S\/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial","volume":"8","author":"G Moncunill","year":"2017","journal-title":"Front Immunol"},{"key":"pone.0317233.ref019","article-title":"Safety and immunogenicity of RTS, S\/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial","volume":"16","author":"L Otieno","year":"2016"},{"issue":"9988","key":"pone.0317233.ref020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"RTS SCTP","year":"2015","journal-title":"LANCET"},{"issue":"2","key":"pone.0317233.ref021","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","article-title":"Safety, immunogenicity, and protective efficacy against controlled human malaria infection of plasmodium falciparum sporozoite vaccine in Tanzanian adults","volume":"99","author":"SA Jongo","year":"2018","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"5","key":"pone.0317233.ref022","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial","volume":"17","author":"MS Sissoko","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pone.0317233.ref023","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.14-0119","article-title":"Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved plasmodium falciparum sporozoites","volume":"91","author":"S Shekalaghe","year":"2014","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"3","key":"pone.0317233.ref024","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S2213-2600(15)00037-5","article-title":"Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: A randomised, placebo-controlled, phase 2 trial","volume":"3","author":"BP Ndiaye","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"38","key":"pone.0317233.ref025","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1016\/j.vaccine.2012.06.054","article-title":"A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants","volume":"30","author":"AA Odutola","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"pone.0317233.ref026","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cid\/cix834","article-title":"Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed bacille calmette-guerin for infants of human immunodeficiency virus-infected mothers: A phase 2 randomized, controlled trial","volume":"66","author":"E Nemes","year":"2018","journal-title":"Clinical Infectious Diseases"},{"issue":"15","key":"pone.0317233.ref027","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.vaccine.2015.02.004","article-title":"The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells\/mm3","volume":"33","author":"GJ Churchyard","year":"2015","journal-title":"Vaccine"},{"issue":"45","key":"pone.0317233.ref028","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/j.vaccine.2014.09.001","article-title":"The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses","volume":"32","author":"BMN Kagina","year":"2014","journal-title":"Vaccine"},{"issue":"21","key":"pone.0317233.ref029","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.vaccine.2016.03.069","article-title":"Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON\u00ae-TB Gold (+) Kenyan adults without evidence of tuberculosis","volume":"34","author":"DS Walsh","year":"2016","journal-title":"Vaccine"},{"key":"pone.0317233.ref030","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100313","article-title":"A phase lb randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa","volume":"21","author":"LG Bekker","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"6","key":"pone.0317233.ref031","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.tube.2014.07.001","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open label randomized controlled trial","volume":"94","author":"OT Idoko","year":"2014","journal-title":"Tuberculosis"},{"issue":"17","key":"pone.0317233.ref032","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b Controlled Trial of M72\/AS01 E Vaccine to Prevent Tuberculosis","volume":"379","author":"O Van Der Meeren","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"32","key":"pone.0317233.ref033","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"A Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"pone.0317233.ref034","article-title":"Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: Randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection","volume":"9","author":"AS Nell","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"pone.0317233.ref035","doi-asserted-by":"crossref","first-page":"454","DOI":"10.5588\/ijtld.14.0608","article-title":"Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination","volume":"19","author":"AC Hesseling","year":"2015","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"issue":"2","key":"pone.0317233.ref036","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00439-16","article-title":"Safety and immunogenicity of the recombinant mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa","volume":"24","author":"AG Loxton","year":"2017","journal-title":"Clinical and Vaccine Immunology"},{"key":"pone.0317233.ref037","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement What is new?","volume":"134","author":"MJ Page","journal-title":"J Clin Epidemiol"},{"issue":"25","key":"pone.0317233.ref038","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final Analysis of a Trial of M72\/AS01 E Vaccine to Prevent Tuberculosis","volume":"381","author":"DR Tait","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"pone.0317233.ref039","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/infdis\/jiu434","article-title":"Delaying BCG vaccination until 8 weeks of age results in robust BCG-specific T-cell responses in HIV-exposed infants","volume":"211","author":"CT Tchakoute","year":"2015","journal-title":"Journal of Infectious Diseases"},{"issue":"25","key":"pone.0317233.ref040","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1016\/j.vaccine.2015.03.070","article-title":"A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants","volume":"33","author":"M Tameris","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"pone.0317233.ref041","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel tuberculosis vaccine ID93\u2008+\u2008GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"A Penn-Nicholson","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"6","key":"pone.0317233.ref042","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/infdis\/jit570","article-title":"Distinct T-Cell Responses When BCG Vaccination Is Delayed from Birth to 6 Weeks of Age in Ugandan Infants","volume":"209","author":"F Lutwama","year":"2014","journal-title":"JOURNAL OF INFECTIOUS DISEASES"},{"issue":"2","key":"pone.0317233.ref043","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination","volume":"379","author":"E Nemes","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"pone.0317233.ref044","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.4049\/jimmunol.1501996","article-title":"Bacillus Calmette\u2013Gu\u00e9rin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses","volume":"197","author":"S Suliman","year":"2016","journal-title":"The Journal of Immunology"},{"issue":"9871","key":"pone.0317233.ref045","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial","volume":"381","author":"MD Tameris","year":"2013","journal-title":"The Lancet"},{"issue":"37","key":"pone.0317233.ref046","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1016\/j.vaccine.2015.03.074","article-title":"A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Gu\u00e9rin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe","volume":"33","author":"HD Geldenhuys","year":"2015","journal-title":"Vaccine"},{"issue":"31","key":"pone.0317233.ref047","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1016\/j.vaccine.2014.04.084","article-title":"Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults","volume":"32","author":"M Hatherill","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"pone.0317233.ref048","article-title":"Efficacy and Safety of the RTS, S\/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites","volume":"11","author":"ST Agnandji","year":"2014","journal-title":"PLoS Med"},{"issue":"4","key":"pone.0317233.ref049","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.vaccine.2019.10.077","article-title":"Safety and immunogenicity of the RTS, S\/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa","volume":"38","author":"L Otieno","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"pone.0317233.ref050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(13)70005-7","article-title":"Efficacy of RTS, S malaria vaccines: individual-participant pooled analysis of phase 2 data","volume":"13","author":"P Bejon","year":"2013","journal-title":"Lancet Infectious Diseases"},{"issue":"9","key":"pone.0317233.ref051","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","article-title":"Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"27","author":"M Oneko","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"pone.0317233.ref052","article-title":"Environmental modifiers of RTS, S\/AS01 malaria vaccine efficacy in Lilongwe, Malawi","volume":"20","author":"GJ Bell","year":"2020","journal-title":"BMC Public Health"},{"issue":"1","key":"pone.0317233.ref053","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41467-019-10195-z","article-title":"Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS, S\/AS01E malaria vaccine efficacy","volume":"10","author":"C Doba\u00f1o","year":"2019","journal-title":"Nat Commun"},{"issue":"10","key":"pone.0317233.ref054","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1080\/21645515.2019.1586040","article-title":"Safety profile of the RTS, S\/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa","volume":"15","author":"Y Mendoza","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"10287","key":"pone.0317233.ref055","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"MS Datoo","year":"2021","journal-title":"Lancet"},{"key":"pone.0317233.ref056","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-019-2637-x","article-title":"Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1\/AS02(A)","volume":"18","author":"AA Berry","year":"2019","journal-title":"Malar J"},{"issue":"1","key":"pone.0317233.ref057","article-title":"RTS, S\/AS01 Malaria Vaccine Efficacy is Not Modified by Seasonal Precipitation: Results from a Phase 3 Randomized Controlled Trial in Malawi","volume":"7","author":"L Han","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"pone.0317233.ref058","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167951","article-title":"Safety, immunogenicity and efficacy of prime-Boost vaccination with chad63 and mva encoding me-trap against plasmodium falciparum infection in adults in senegal","volume":"11","author":"VA Mensah","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"pone.0317233.ref059","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-016-1466-4","article-title":"Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25\u2013545]) in healthy Malian adults in Bandiagara","volume":"15","author":"MA Thera","year":"2016","journal-title":"Malar J"},{"issue":"1","key":"pone.0317233.ref060","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1186-4","article-title":"Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS, S\/AS01E vaccination in African children","volume":"16","author":"I Ubillos","year":"2018","journal-title":"BMC Med"},{"issue":"21","key":"pone.0317233.ref061","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic Diversity and Protective Efficacy of the RTS, S\/AS01 Malaria Vaccine","volume":"373","author":"DE Neafsey","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0317233.ref062","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-021-10294-x","article-title":"Potential effect modification of RTS, S\/AS01 malaria vaccine efficacy by household socio-economic status","volume":"21","author":"S Gyaase","year":"2021","journal-title":"BMC Public Health"},{"issue":"11","key":"pone.0317233.ref063","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention","volume":"385","author":"D Chandramohan","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"pone.0317233.ref064","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"MS Datoo","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"pone.0317233.ref065","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1473-3099(19)30300-7","article-title":"Long-term incidence of severe malaria following RTS, S\/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial","volume":"19","author":"H Tinto","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pone.0317233.ref066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-021-04020-6","article-title":"Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48\/45) in individuals living in Brazilian malaria-endemic areas","volume":"21","author":"BO Baptista","year":"2022","journal-title":"Malar J"},{"issue":"12","key":"pone.0317233.ref067","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1207564","article-title":"Four-Year Efficacy of RTS, S\/AS01E and Its Interaction with Malaria Exposure","volume":"368","author":"A Olotu","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"pone.0317233.ref068","article-title":"Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum","author":"MD Langowski","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"4","key":"pone.0317233.ref069","article-title":"Phase i trial evaluating the safety and immunogenicity of candidate tb vaccine mva85a, delivered by aerosol to healthy m.Tb-infected adults","volume":"9","author":"M Riste","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"pone.0317233.ref070","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-022-00534-5","article-title":"Needle-free, spirulina-produced Plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice","volume":"7","author":"T Saveria","year":"2022","journal-title":"NPJ Vaccines"},{"key":"pone.0317233.ref071","unstructured":"WHO. Malaria vaccines: Preferred product characteristics and development considerations. 2022."},{"key":"pone.0317233.ref072","unstructured":"WHO. WHO Preferred Product Characteristics for Therapeutic Vaccines to Improve Tuberculosis Treatment Outcomes. 2019 [cited 2024 Oct 19]; Available from: http:\/\/apps.who.int\/bookorders."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:38:10Z","timestamp":1737725890000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317233"}},"subtitle":[],"editor":[{"given":"Luzia H.","family":"Carvalho","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0317233","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.28.24302787","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}